Retrospective Cohort Study Evaluating the Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Tyrosine Kinase Inhibitor-Associated Toxicity in Advanced Renal Cell Carcinoma
Journal of Urologic Oncology · 31.07.2026 · 24 (2) · 162-171
DOI: 10.22465/juo.265200060003 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Urologic Oncology, erschienen am 31.07.2026. Verfasst von Theodore Joseph Miller und 6 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Purpose
Tyrosine kinase inhibitors (TKIs) used to treat advanced renal cell carcinoma are associated with clinically significant toxicities, including hypertension and acute kidney injury. Because angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEis/ARBs) have established antihypertensive and renoprotective effects, they may be associated with lower rates of TKI-related toxicity. This study evaluated the association between ACEi/ARB use and TKI-associated toxicity.Materials and Methods: We conducted a retrospective observational cohort study using data from the United States TriNetX research network and Penn State Hershey Medical Center (HMC). Patients receiving TKI therapy were stratified according to concurrent ACEi/ARB use. Primary endpoints included kidney function parameters (urine protein, blood urea nitrogen [BUN], and creatinine) and blood pressure measurements. Secondary outcomes included TKI dose discontinuation events. Group comparisons were performed using the Wilcoxon rank-sum test for continuous variables and Fisher exact test for categorical outcomes.
Results
In the combined TriNetX and HMC cohorts, ACEi/ARB use was associated with a statistically significant reduction in documented proteinuria diagnoses (absolute reduction, 19.1%; p=0.036). No significant differences were observed in BUN levels or systolic or diastolic blood pressure. In the HMC cohort, ACEi/ARB use was associated with lower creatinine levels at 4–6 weeks after ACEi/ARB initiation (mean reduction, -0.4 mg/dL; p=0.050) and a 13.7% absolute reduction in TKI discontinuation events. Because of the retrospective observational design and absence of adjustment for baseline confounders, these findings should be interpreted as associative.
Conclusion
ACEi/ARB use was associated with lower rates of proteinuria, possible improvement in creatinine levels, and fewer treatment discontinuation events. These findings suggest that ACEis/ARBs may help reduce selected TKI-related toxicities. Prospective studies are needed to clarify dose-dependent and temporal effects in patients with renal or vascular comorbidities.
Zitieren
APA
Miller, T. J., Zhu, J., Wheelden, M., Maddukuri, A., Elias, M., Trivedi, N., & Joshi, M. (2026). Retrospective Cohort Study Evaluating the Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Tyrosine Kinase Inhibitor-Associated Toxicity in Advanced Renal Cell Carcinoma. Journal of Urologic Oncology, 24(2), 162-171. https://doi.org/10.22465/juo.265200060003
Vancouver
Miller TJ, Zhu J, Wheelden M, Maddukuri A, Elias M, Trivedi N, et al. Retrospective Cohort Study Evaluating the Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Tyrosine Kinase Inhibitor-Associated Toxicity in Advanced Renal Cell Carcinoma. Journal of Urologic Oncology. 2026;24(2):162-171. doi:10.22465/juo.265200060003
BibTeX
@article{Miller2026,
author = {Miller, Theodore Joseph and Zhu, Junjia and Wheelden, Megan and Maddukuri, Ashok and Elias, Michael and Trivedi, Naman and Joshi, Monika},
title = {Retrospective Cohort Study Evaluating the Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Tyrosine Kinase Inhibitor-Associated Toxicity in Advanced Renal Cell Carcinoma},
journal = {Journal of Urologic Oncology},
year = {2026},
volume = {24},
number = {2},
pages = {162--171},
doi = {10.22465/juo.265200060003}
}
EUVIMED